Douglas Petersen
Douglas Petersen is PhRMA’s Vice President for international trade. Previously, he was international trade counsel for the U.S. Senate Committee on Finance, an international trade attorney with White & Case LLP and a trade policy analyst at the Cato Institute. He received a law degree from New York University, a graduate degree from the London School of Economics, and undergraduate degrees from the University of Utah.
Strong Trade Policies Protect American Workers and Biopharmaceutical Innovation
USTR remembers—three years later—that it announced a trade initiative with Europe
No Region Left Behind: USTR expands its unambitious trade agenda to the western hemisphere
Why won’t USTR strengthen medical supply chains with America’s allies?
The Biden Administration has failed to advance an inclusive, worker-centered trade agenda
Four ways that America’s biopharmaceutical industry supports jobs and fuels economic growth
Will the administration capitalize on the Indo-Pacific Economic Framework to drive medical innovation?
Biden administration should prioritize innovation in U.S.-Taiwan Initiative on 21st-Century Trade
PhRMA submission to USTR calls for urgent defense of American innovation abroad
PhRMA encourages Biden administration to pursue ambitious Indo-Pacific Economic Framework
PhRMA submission to 2022 National Trade Estimate Report underscores need for pro-innovation U.S. trade policy to combat COVID-19
Strengthening the WTOs global trade and health agenda
U.S. trade policy must prioritize American biopharmaceutical innovation and patient access
PhRMA submission to 2020 National Trade Estimate Report: Urgent action required to protect U.S. biopharmaceutical innovation
World Trade Month: How we can expand world-class pro-innovation standards
Fact Check: Biologics, regulatory data protection and the United States-Mexico-Canada Agreement
PhRMA submission to the 2019 National Trade Estimate Report urges action to protect U.S. biopharmaceutical innovation
Douglas Petersen